RxDoctor Payments Data

Brian Vicuna, MD

Medical Oncology · Las Vegas, NVNPI 1275755670

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $65,784 of the $107,371 with a category attached, or 61.3%. It is spread thinly across 60 manufacturers, the largest accounting for just 15.1%.

$107,371in general payments, 2019–2025

Across 898 payments — averaging $119.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$16K
  • AbbVie$15K
  • Gilead$10K
  • Janssen Scientific Affairs, LLC$7K
  • Pfizer$5K
  • Taiho Oncology, Inc.$4K
  • plus $49K from 54 others
$1,165,784in research payments, 2019–2025

Across 307 payments — averaging $3797.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Genentech, Inc.$331K
  • Exelixis Inc.$253K
  • Ipsen Bioscience Inc.$176K
  • F. Hoffmann-la Roche AG$104K
  • GSK$96K
  • E.r. Squibb & Sons, L.L.C.$93K
  • plus $112K from 6 others

What the payments were for

  • Consulting fees$65,78461%
  • Speaking & faculty fees$14,94314%
  • Travel & lodging$3,3633%
  • Food & beverage$18,40817%
  • Education$1,6292%
  • Gifts$1,9652%
  • Other$1,2801%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca(2 entities)60$16,194
AbbVie42$15,273
Gilead(2 entities)22$10,327
Janssen Scientific Affairs, LLC9$6,551
Pfizer49$4,842
Taiho Oncology, Inc.4$4,307
Incyte Corporation20$4,152
Novartis73$4,070
Bristol Myers Squibb19$4,055
Ipsen Biopharmaceuticals, Inc12$3,541
Bayer24$3,380
Blueprint Medicines Corporation9$3,303
Takeda Pharmaceuticals U.S.A., Inc.9$2,313
Lilly USA, LLC12$2,288
ADC Therapeutics America, Inc.5$2,222
Johnson & Johnson(2 entities)50$2,210
Eisai Inc.6$1,902
Daiichi Sankyo Inc.93$1,686
Exelixis Inc.9$1,461
Array Biopharma Inc7$1,353
Amgen42$1,091
Aadi Bioscience, Inc.2$1,018
Beigene USA, Inc.6$823
Astellas Pharma US Inc22$727
Genentech USA, Inc.24$572
Beigene, Ltd.1$525
Sobi, Inc26$435
Sanofi18$423
Seagen Inc.14$403
Sanofi-aventis U.S. LLC4$350
EMD Serono, Inc.15$325
Jazz Pharmaceuticals Inc.5$307
GSK11$306
Chiesi USA, Inc.1$300
AVEO Pharmaceuticals, Inc.5$286
Merck14$279
Tempus AI, Inc17$277
E.r. Squibb & Sons, L.L.C.8$261
Karyopharm Therapeutics Inc.9$223
Pharmacyclics LLC, An Abbvie Company10$214
Dendreon Pharmaceuticals LLC8$201
Stemline Therapeutics Inc.6$178
Sumitomo Pharma America, Inc.7$165
Agios Pharmaceuticals, Inc.6$154
Sirtex Medical Inc1$146
Boehringer Ingelheim5$130
Genentech, Inc.4$128
Mirati Therapeutics, Inc.5$109
Regeneron Healthcare Solutions, Inc.5$102
Genmab U.S., Inc.4$98
Global Blood Therapeutics, Inc.4$83
Intuitive Surgical1$82
Rigel Pharmaceuticals, Inc.3$77
AMAG Pharmaceuticals, Inc.3$63
Dova Pharmaceuticals3$57
Blue Earth Diagnostics1$56
Novocure Inc.2$56
Heron Therapeutics, Inc.3$50
Adaptive Biotechnologies Corporation2$48
Clovis Oncology, Inc.3$47

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few medical oncology providers in Nevadato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$4,844,157
Medicare patients
908
Services billed
271,156

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide63$781,798
IbrancePalbociclib41$630,034
XtandiEnzalutamide36$484,062
PomalystPomalidomide24$432,603
VerzenioAbemaciclib28$426,747
Lenalidomide28$378,228
VenclextaVenetoclax15$212,201
RevlimidLenalidomide14$204,680
NubeqaDarolutamide14$189,161
TasignaNilotinib Hcl20$187,692
IclusigPonatinib Hcl11$181,804
EliquisApixaban209$164,443
OxbrytaVoxelotor11$86,221
XareltoRivaroxaban81$81,165
Abiraterone Acetate38$32,750

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada, Xarelto$2,210$862,964144 claims
PfizerIbrance, Eliquis$4,842$794,477250 claims
Astellas Pharma US IncXtandi$727$484,06236 claims
E.r. Squibb & Sons, L.L.C.Pomalyst$261$432,60324 claims
Lilly USA, LLCVerzenio$2,288$426,74728 claims
AbbVieVenclexta$15,273$212,20115 claims
Bristol Myers SquibbRevlimid$4,055$204,68014 claims
BayerNubeqa$3,380$189,16114 claims
NovartisTasigna$4,070$187,69220 claims
Takeda Pharmaceuticals U.S.A., Inc.Iclusig$2,313$181,80411 claims
Global Blood Therapeutics, Inc.Oxbryta$83$86,22111 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$6,551$32,75038 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few medical oncology providers in Nevadaon file to place this against a meaningful peer group, so we don't.

Other medical oncology in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →